Trial · NCT02431806
Participant flow28
How many started, completed or left each group, period by period.
1 to 20 of 28
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-blind Treatment Period | STARTED | Placebo | 142 | |
| Double-blind Treatment Period | STARTED | Levomilnacipran 40 mg/Day | 136 | |
| Double-blind Treatment Period | STARTED | Levomilnacipran 80 mg/Day | 139 | |
| Double-blind Treatment Period | STARTED | Fluoxetine 20 mg/Day | 135 | |
| Double-blind Treatment Period | Safety Population | Placebo | 141 | |
| Double-blind Treatment Period | Safety Population | Levomilnacipran 40 mg/Day | 134 | |
| Double-blind Treatment Period | Safety Population | Levomilnacipran 80 mg/Day | 138 | |
| Double-blind Treatment Period | Safety Population | Fluoxetine 20 mg/Day | 134 | |
| Double-blind Treatment Period | COMPLETED | Placebo | 117 | |
| Double-blind Treatment Period | COMPLETED | Levomilnacipran 40 mg/Day | 115 | |
| Double-blind Treatment Period | COMPLETED | Levomilnacipran 80 mg/Day | 107 | |
| Double-blind Treatment Period | COMPLETED | Fluoxetine 20 mg/Day | 109 | |
| Double-blind Treatment Period | NOT COMPLETED | Placebo | 25 | |
| Double-blind Treatment Period | NOT COMPLETED | Levomilnacipran 40 mg/Day | 21 | |
| Double-blind Treatment Period | NOT COMPLETED | Levomilnacipran 80 mg/Day | 32 | |
| Double-blind Treatment Period | NOT COMPLETED | Fluoxetine 20 mg/Day | 26 | |
| Double-blind Down-taper Period | STARTED | Placebo | 111 | |
| Double-blind Down-taper Period | STARTED | Levomilnacipran 40 mg/Day | 109 | |
| Double-blind Down-taper Period | STARTED | Levomilnacipran 80 mg/Day | 104 | |
| Double-blind Down-taper Period | STARTED | Fluoxetine 20 mg/Day | 107 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02431806/flow